semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Cancer Female breast cancer patients at the age of >= 18 years and <= 65 years who received first treatment； 2. Pathologically confirmed HER2-positive invasive breast cancer（which is defined as the immunohistochemistry score of > 10% immunoreactive cells being 3+ or in situ hybridization results showing HER2 gene amplification），regardless of hormone receptor status (ER and PR)； 3. According to the 2019 CSCO BC guidelines: When HER-2 positive is used as the standard for preoperative neoadjuvant therapy for breast cancer, the tumor is larger than 2 cm； 4. The Eastern Tumor Collaborative Group (ECOG) has a physical status score of ≤1； 5. The functional level of the main organs must meet the following requirements ： 1) blood routine test: hemoglobin (Hb) ≥ 90g/L;Neutrophils (ANC) ≥ 1.5 × 10^9/L; platelet count (PLT) ≥ 90 × 10^9/L; 2) Blood biochemistry: Total bilirubin (TBIL) ≤ 1.5 upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; Urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN; 3) Heart color ultrasound: Left ventricular ejection fraction (LVEF) ≥ 55%; 6. Women of childbearing age, tested negative for serum pregnancy test 7 days before randomization，and willing to use appropriate methods during the trial and within 8 weeks after the last administration of the test drug; 7. A volunteer to participate in the study; provision of written informed consent; good compliance and willing to cooperate during the follow-up  Known history of hypersensitivity to pyrotinib or any of it components; 2. Patients have previously received antitumor treatment or radiation therapy for any malignant tumor (except for cervical carcinoma in situ and basal cell carcinoma that have been cured); 3. Patients underwent major breast cancer-free surgery within 4 weeks and have not fully recovered; 4. Subjects that are unable to swallow tablets,intestinal obstruction or dysfunction of gastrointestinal absorption; 5. Patients with severe heart disease or discomfort who cannot be treated; 6. The patient suffers from mental illness or psychotropic substance abuse and cannot cooperate; 7. Pregnant or lactating women; 8. Less than 4 weeks from the last clinical trial; 9. Patients participating in other clinical trials at the same time 10. The researchers think inappropriate
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-22.0,  Acute Myeloid Leukemia All patients must be enrolled on APEC14B1 and consented to Screening (Part A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens must be done according to the Manual of Procedures). Risk stratification will not be possible without the submission of viable samples. Given there are multiple required samples, bone marrow acquisition techniques such as frequent repositioning or performing bilateral bone marrow testing should be considered to avoid insufficient material for required studies. Consider a repeat marrow prior to starting treatment if there is insufficient diagnostic material for the required studies Patients must be less than 22 years of age at the time of study enrollment Patient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease Patient must have 1 of the following >= 20% bone marrow blasts (obtained within 14 days prior to enrollment) In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy < 20% bone marrow blasts with one or more of the genetic abnormalities (sample obtained within 14 days prior to enrollment) A complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment) ARM C: Patient must be >= 2 years of age at the time of Late Callback ARM C: Patient must have FLT3/ITD allelic ratio > 0.1 as reported by Molecular Oncology  Patients with myeloid neoplasms with germline predisposition are not eligible Fanconi anemia Shwachman Diamond syndrome Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Any other known bone marrow failure syndrome Any concurrent malignancy Juvenile myelomonocytic leukemia (JMML) Philadelphia chromosome positive AML Mixed phenotype acute leukemia Acute promyelocytic leukemia
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female or male sex. 2. Diagnosis (confirmed by clinical review) of A/MBC, defined as breast cancer at stage IIIB, stage IIIC, stage IV or identified as having distant metastasis. 3. Age ≥18 years at A/MBC diagnosis. 4. Initiated a CDK4/6i in combination with an AI as initial endocrine-based therapy after A/MBC diagnosis on or after 2/3/2015 and before 4/1/2019. •Note that the date of the start of the period reflects the month that the first CDK4/6i (ie, Palbociclib) received U.S. FDA approval. 5. Evidence of ER or PR positive disease, or absence of any indication of ER and PR negative disease closest to A/MBC diagnosis (ie, patients are eligible without affirmative indication of ER/PR+ status as long as ER/PR indication is not present). 6. Evidence of HER2 negative disease, or absence of any indication of HER2 positive disease closest to A/MBC diagnosis (ie, patients are eligible without affirmative indication of HER2 status as long as HER2+ indication is not present)  Enrollment in an interventional clinical trial for A/MBC during the study observation period
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Neoplasm Female cT2 cN0/1 breast cancer Scheduled for neoadjuvant chemotherapy Informed consent  Previous malignancy at another site Synchronous breast cancer at diagnosis Distant metastasis at diagnosis Clinically involved axilla (cN1) after neoadjuvant chemotherapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Triple Negative Breast Cancer Patients with histologically confirmed invasive adenocarcinoma of the breast Triple negative breast cancer: hormone receptor negative (ER < 10% and PgR < 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory Clinical stage at presentation: T1-4, N0-3, M0, with indications for neoadjuvant chemotherapy Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred Patients should have undergone adequate tumor excision in the breast and lymph nodes after neoadjuvant chemotherapy Residual invasive disease must be ≥1cm in the breast, and/or have positive axillary lymph nodes observed on pathologic exam after neoadjuvant chemotherapy ECOG Performance Status: 0-1 Patients without severe heart, lung, liver and kidney disease Adequate hematologic and end-organ function No more than 6 weeks may elapse between definitive breast surgery and randomization  Previous neoadjuvant chemotherapy with anthracycline or other drugs (except platinum and taxanes) Previous neoadjuvant chemotherapy with platinum or taxanes alone Patients have received other adjuvant therapy Comprehensive medical examinations have revealed distant metastases before randomization Patients who are not suitable for anthracycline evaluated by investigators Prior history of other malignancy (except carcinoma in situ)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HER2-negative Breast Cancer Male or female subject aged ≥ 18 years Her2 negative on immunohistochemistry or nonamplified breast cancer Metastatic or recurrent unresectable breast cancer Triple-negative breast cancer without prior treatment in the metastatic setting Hormone receptor-positive breast cancer that has exhausted or refused all endocrine monotherapy or endocrine therapeutic combinatorial options Willing and capable (per treating investigator's assessment) to undergo a baseline biopsy Patient can safely undergo tumor biopsy The tumor is reasonably accessible to biopsy The tumor is amenable to biopsy, e.g. does not abut neurovascular structures If the patient receives anticoagulation, anticoagulation can be safely withheld to accommodate for tissue acquisition  Diagnosis of any other malignancy within 2 years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration) or radiotherapy and currently with no evidence of disease or symptoms is allowed The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions Myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class IIB) or a serious cardiac arrhythmia requiring medication Renal or liver disease that prohibits the patient from receiving at least single-agent full recommended dose chemotherapy The patient cannot safely undergo biopsy for reasons including but not limited to Tumor is inaccessible The patient requires anticoagulation which cannot be withheld The patient has bleeding diathesis Any other reason that would render tumor tissue acquisition a high-risk procedure Patient cannot or is unwilling to receive chemotherapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Triple-negative Breast Cancer HER2-positive Breast Cancer Triple-negative or HER2-positve invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration or core needle biopsy Underwent computed tomography for assessment of axillary lymph node status before and after neoadjuvant chemotherapy Attend the study voluntarily, sign the informed consent  Contradiction for adjuvant chemotherapy Contradiction for proceeding surgery
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Breast Cancer All female participants eligible for neoadjuvant chemotherapy and planning surgical treatment 2. Able to give informed consent  All female particpants having neoadjuvant chemotherapy as palliative treatment with no surgery planned 2. Unable to provide informed consent 3. Unable to have breast MRI scan due to clautrophobia or allergy to gadolineum
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer early-stage invasive breast cancer positive for estrogen receptor and / or progesterone receptor is pathologically confirmed patients who have completed standard endocrine therapy for 5 years without recurrence and metastasis 70 years old patients with one of the following six manifestations: KI67 ≥ 30%; tumor size > 2 cm; positive lymph nodes; histological grade III; vascular cancer thrombus; HER-2 gene overexpression or amplification  with a history of other malignancies patients who have severe abnormalities in important organs, such as the heart, liver, and kidney or who cannot be tolerant to extended treatment due to poor constitution patients with severe osteoporosis or dyslipidemia, or those who cannot tolerate endocrine therapy  patients who have participated in other clinical trials
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Invasive Breast Cancer Mastectomy, Segmental Margins of Excision Newly diagnosed women with biopsy-verified invasive breast cancer planned for breast conserving surgery Age > 18 year  Previous surgery for pre-malignant or malignant lesions in the breast Planned mastectomy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-69.0,  Breast Cancer Patients Health, Subjective first occurrence breast cancer diagnosed from Jan 1, 2020 non-metastatic cancer stage 0-III Invasive tumors must be HER2 positive (regardless of ER, PR) or ER negative (may later other ER+ if not conflict with recruitment for EMIT/OPTIMA)  None
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Breast Cancer Early stage Breast Cancer DCIS gr III  Not able to read Norwegian Not able to communicate in Norwegian Previously diagnosed with cancer Dementia
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Carcinoma, Ductal, Breast Invasive Breast Cancer IMAGE Adult over 19 years-old Breast Ductal Carcinoma in-situ patients who diagnosed preoperative tissue biopsy A person who understands this study and agrees with willingness to participate  Ductal Carcinoma in-situ which diagnosed excisional biopsy When there is no lesion that can be discriminated from magnetic resonance imaging Neoadjuvant chemotherapy patients Patients who have complication (hematoma, abscess etc.) after preoperative biopsy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Breast Cancer Women in screening and symptomatic clinics aged >35 years with breast masses scored as M4 or M5 (mammographically suspicious or highly suspicious of malignancy) and U5 (ultrasonically highly suspicious of malignancy) and/or MRI5 (highly suspicious of malignancy on magnetic resonance imaging) and U5 and/or have histologically proven breast cancer and who have ipsilateral axillary lymph nodes which are indeterminate or suspicious for metastatic disease (A3, 4 or 5), as determined by individual breast unit have given written informed consent for the study  Women who are on anticoagulants, antiplatelet drugs (inc. aspirin) or have known clotting disorders Previous ipsilateral axillary surgery Target lymph node not suitable for needle biopsy due to its close proximity to critical structures such as major blood vessels Unable to give written informed consent in English
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Brain Tumor Brain tumor subjects (27) informed consent age equal to or greater than 19 years (age of majority in Nebraska) brain tumor that requires surgery primary or metastatic brain tumor 2. Healthy subjects (3) informed consent age equal to or greater than 19 years (age of majority in Nebraska) healthy subject with no know neurocognitive deficiencies  any contraindication to MRI (i.e. implanted devices) inappropriate body habitus for MRI no capacity to understand the study the study or consent to it positive pregnancy test in females end stage renal disease or severe renal dysfunction severe anxiety disorder metabolic encephalopathy significant medical co-morbidities precluding a safe surgery need for sedation for MRI